AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12631501 — intervention group
Group type: COMPARATOR
Intervention: No Food Deprivation without Restriction (No Dep/No Res)
Number of subjects: 40
Study 10697029 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 plus carboplatin (AUC = 6)
Number of subjects: 127
Study 10697029 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus gemcitabine 1,000 mg/m2 on days 1 and 8 every 3 weeks
Number of subjects: 127
Study 9375939 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (100 mg)
Number of subjects: 0
Study 9375939 — intervention group
Group type: COMPARATOR
Intervention: Mibefradil
Number of subjects: 0
Study 8222793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (200 mg, bid)
Number of subjects: 301
Study 8222793 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (250 mg, tid)
Number of subjects: 301
Study 8222793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil
Number of subjects: 301
Study 8222793 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 301
Study 3532293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg once daily
Number of subjects: 574
Study 3532293 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 574
Study 3532293 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 574
Study 31609709 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic and antimycotic impregnated PICC (IP-PICC)
Number of subjects: 71
Study 31609709 — intervention group
Group type: COMPARATOR
Intervention: Standard PICC (S-PICC)
Number of subjects: 71
Study 30497658 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US)
Number of subjects: 50
Study 30497658 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 50
Study 26962236 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 246
Study 24930383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 97
Study 24930383 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 97
Study 24930383 — intervention group
Group type: COMPARATOR
Intervention: Combined groups
Number of subjects: 97
Study 22446678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic warm-up (DWU)
Number of subjects: 45
Study 22446678 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching warm-up (SWU)
Number of subjects: 45
Study 22446678 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 45
Study 20726877 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate withdrawal (IW)
Number of subjects: 25
Study 20726877 — intervention group
Group type: COMPARATOR
Intervention: Delayed withdrawal (DW)
Number of subjects: 25
Study 18234203 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron carboxymaltose (up to 3 weekly doses of 1000 mg maximum, applied in 15 min)
Number of subjects: 344
Study 18234203 — intervention group
Group type: COMPARATOR
Intervention: Ferrous sulfate (100 mg twice daily for 12 weeks)
Number of subjects: 344
Study 16158748 — intervention group
Group type: EXPERIMENTAL
Intervention: Bactisporin (probiotic based on Bacillus subtilis, strain 3H)
Number of subjects: 36
Study 16158748 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative etiotropic therapy
Number of subjects: 36
Study 14510829 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV; 1,000 to 3,000 mg/day)
Number of subjects: 846
Study 14510829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 846
Study 10393285 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive education (MIE)
Number of subjects: 100
Study 10393285 — intervention group
Group type: COMPARATOR
Intervention: Less intensive education (LIE)
Number of subjects: 100
Study 8897037 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml.kg‐1 absolute ethanol added to orange juice in a 1:6 ratio
Number of subjects: 7
Study 8897037 — intervention group
Group type: COMPARATOR
Intervention: Orange juice (7 ml.kg‐1)
Number of subjects: 7
Study 1854178 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 105
Study 1854178 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanate
Number of subjects: 105
Study 6639917 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with P:S value of 2.0
Number of subjects: 20
Study 6639917 — intervention group
Group type: COMPARATOR
Intervention: Diet with P:S value of 1.3
Number of subjects: 20
Study 31541874 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification (CBM)
Number of subjects: 36
Study 31541874 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 36
Study 31541874 — intervention group
Group type: EXPERIMENTAL
Intervention: AUD patients
Number of subjects: 36
Study 31541874 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 25703488 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavior Therapy (TF-CBT) + parenting classes
Number of subjects: 43
Study 25703488 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (parenting classes)
Number of subjects: 43
Study 24528195 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based telematic system (two face-to-face and five telematic appointments)
Number of subjects: 154
Study 24528195 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face appointments (seven appointments)
Number of subjects: 154
Study 24528195 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based telematic system
Number of subjects: 154
Study 24528195 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face appointments
Number of subjects: 154
Study 21935752 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one self-management educational intervention focusing on inhaler technique, smoking cessation, and using a COPD action plan.
Number of subjects: 99
Study 21935752 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 99
Study 21935752 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one self-management educational intervention (for patients with low health literacy).
Number of subjects: 99
Study 21935752 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one self-management educational intervention (for patients with higher health literacy).
Number of subjects: 99
Study 19020859 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron lung ventilation (ILV)
Number of subjects: 141
Study 19020859 — intervention group
Group type: COMPARATOR
Intervention: Mask ventilation (NPPV)
Number of subjects: 141
Study 19020859 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (ILV and NPPV)
Number of subjects: 141
Study 17970256 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-and-work (n = 28)
Number of subjects: 56
Study 17970256 — intervention group
Group type: COMPARATOR
Intervention: Work-only (n = 28)
Number of subjects: 56
Study 15447890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 eggs/day (EGG period; 518 additional mg cholesterol)
Number of subjects: 54
Study 15447890 — intervention group
Group type: COMPARATOR
Intervention: Egg whites (SUB period; 0 additional mg cholesterol)
Number of subjects: 54
Study 11279634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 (10 to 150 microg/kg)
Number of subjects: 0
Study 11279634 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim (5 or 10 microg/kg as a single dose, then daily for 7 days)
Number of subjects: 0
Study 11279634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐8315 (60‐150 microg/kg)
Number of subjects: 0
Study 11279634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 25‐8315
Number of subjects: 0
Study 11279634 — intervention group
Group type: COMPARATOR
Intervention: Ro 25‐8315 and Filgrastim
Number of subjects: 0
Study 9477750 — intervention group
Group type: EXPERIMENTAL
Intervention: Bassini repair
Number of subjects: 324
Study 9477750 — intervention group
Group type: EXPERIMENTAL
Intervention: McVay repair
Number of subjects: 324
Study 9477750 — intervention group
Group type: EXPERIMENTAL
Intervention: Shouldice repair
Number of subjects: 324
Study 7633711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 3923
Study 7633711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3923
Study 7633711 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide or placebo
Number of subjects: 3923
Study 2540054 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg/day)
Number of subjects: 8
Study 2540054 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (60-120 mg/day)
Number of subjects: 8
Study 2540054 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 8
Study 989578 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum carcinoembryonic antigen (CEA) assay
Number of subjects: 377
Study 989578 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide liver scan
Number of subjects: 377
Study 31578918 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 77
Study 30192802 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab treatment during stimulation with IFNγ and TNFα
Number of subjects: 0
Study 30192802 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical inhibition of EGFR signaling (using MEK1/2 inhibitor PD98059 and JNK inhibitor SP600125)
Number of subjects: 0
Study 30192802 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with cetuximab and MEK1/2 or JNK inhibitor
Number of subjects: 0
Study 30192802 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulation with IFNγ and TNFα
Number of subjects: 0
Study 30192802 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking of EGFR with cetuximab
Number of subjects: 0
Study 27342447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (100 ng/mL target plasma concentration)
Number of subjects: 27
Study 27342447 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous saline)
Number of subjects: 27
Study 24621831 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium (Dex‐0 group, n=319)
Number of subjects: 954
Study 24621831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.1 mg/kg (Dex‐1 group, n=320)
Number of subjects: 954
Study 24621831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.2 mg/kg (Dex‐2 group, n=315)
Number of subjects: 954
Study 22874685 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stent
Number of subjects: 60
Study 22874685 — intervention group
Group type: COMPARATOR
Intervention: T-tube
Number of subjects: 60
Study 20398482 — intervention group
Group type: EXPERIMENTAL
Intervention: Benidipine (8 mg/d)
Number of subjects: 236
Study 20398482 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/d)
Number of subjects: 236
Study 17335828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 17335828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17335828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil with weight loss
Number of subjects: 0
Study 17335828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil with diabetes or hyperinsulinemia
Number of subjects: 0
Study 17335828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil without weight loss
Number of subjects: 0
Study 15880810 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gold
Number of subjects: 65
Study 15880810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 15880810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 65
Study 11689270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral HRT
Number of subjects: 33
Study 11689270 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal HRT
Number of subjects: 33
Study 11689270 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 33
Study 9632032 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg daily
Number of subjects: 99
Study 9632032 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg daily
Number of subjects: 99
Study 7930052 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-psychopathy group
Number of subjects: 54
Study 7930052 — intervention group
Group type: COMPARATOR
Intervention: High-psychopathy group
Number of subjects: 54
Study 7930052 — intervention group
Group type: EXPERIMENTAL
Intervention: Antisocial behavior factor of psychopathy
Number of subjects: 54
Study 3284322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (60 or 80 mg 3 times daily)
Number of subjects: 1650
Study 1983801 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric Lavage
Number of subjects: 0
Study 1983801 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Number of subjects: 0
Study 1983801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipecacuanha
Number of subjects: 0
Study 1983801 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 1095307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine, 16 mg, 3-times daily for 3 weeks
Number of subjects: 36
Study 1095307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 1095307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromhexine and Placebo
Number of subjects: 36
Study 30772115 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Research Engagement Intervention
Number of subjects: 133
Study 30772115 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 133
Study 30772115 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 133
Study 28124536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical chondroïtin sulphate (CS) 2%
Number of subjects: 36
Study 28124536 — intervention group
Group type: COMPARATOR
Intervention: Intravesical dimethyl sulphoxide (DMSO) 50%
Number of subjects: 36
Study 25887128 — intervention group
Group type: EXPERIMENTAL
Intervention: Algisite™ M (calcium alginate dressing)
Number of subjects: 0
Study 25887128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuticerin™ (smooth acetate gauze with water-repellent ointment)
Number of subjects: 0
Study 25887128 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbact® (gauze mesh coated with DACC and amorphous hydrogel)
Number of subjects: 0
Study 25887128 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23343804 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (CHC)
Number of subjects: 60
Study 23343804 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (GIC)
Number of subjects: 60
Study 23343804 — intervention group
Group type: COMPARATOR
Intervention: Negative control (wax)
Number of subjects: 60
Study 20647950 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity low-volume (50 km) training group (HILV-group)
Number of subjects: 26
Study 20647950 — intervention group
Group type: COMPARATOR
Intervention: High-volume (70 km) low-intensity training group (HVLI-group)
Number of subjects: 26
Study 19214143 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (5-lipoxygenase inhibitor)
Number of subjects: 577
Study 19214143 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (cys-leukotriene receptor antagonist)
Number of subjects: 577
Study 19214143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 17264955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TA)
Number of subjects: 14
Study 17264955 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured endothelial cells treated with TA
Number of subjects: 14
Study 15536460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ALF after rifampin
Number of subjects: 10
Study 15536460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ALF after troleandomycin (TAO)
Number of subjects: 10
Study 15536460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ALF after grapefruit juice
Number of subjects: 10
Study 15536460 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 10
Study 11409217 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking
Number of subjects: 64
Study 11409217 — intervention group
Group type: COMPARATOR
Intervention: Counting aloud
Number of subjects: 64
Study 9493975 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF (Cyclophosphamide 400 mg/m2, Fluorouracil 400 mg/m2, and Methotrexate 40 mg/m2)
Number of subjects: 282
Study 9493975 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no adjuvant therapy)
Number of subjects: 282
Study 9493975 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutated p53 group
Number of subjects: 282
Study 8066587 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 8066587 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making participation
Number of subjects: 0
Study 3355474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 8
Study 3355474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30691748 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Dysphagia Therapy (TDT) - sensorimotor exercises and swallowing maneuvers
Number of subjects: 20
Study 30691748 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) - diet prescription and postural changes
Number of subjects: 20
Study 28834296 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (group B)
Number of subjects: 188
Study 28834296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 188
Study 26890400 — intervention group
Group type: EXPERIMENTAL
Intervention: Ironson‐Woods Spirituality/Religiousness Index (IWSRI)
Number of subjects: 300
Study 23646330 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Essix retainers
Number of subjects: 36
Study 23646330 — intervention group
Group type: COMPARATOR
Intervention: Full-coverage Essix retainers
Number of subjects: 36
Study 21750697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid malaria diagnostic tests (RDTs) by community health workers (CHWs)
Number of subjects: 2930
Study 21750697 — intervention group
Group type: COMPARATOR
Intervention: Clinical diagnosis (CD) by community health workers (CHWs)
Number of subjects: 2930
Study 19396790 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective laser trabeculoplasty (SLT)
Number of subjects: 120
Study 19396790 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 120
Study 16882893 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 21
Study 16882893 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine and betamethasone
Number of subjects: 21
Study 16882893 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (alone or in combination with betamethasone)
Number of subjects: 21
Study 15361745 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face interviews
Number of subjects: 34
Study 15361745 — intervention group
Group type: COMPARATOR
Intervention: Phone interviews
Number of subjects: 34
Study 11726064 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 2
Study 11726064 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 2
Study 9204223 — intervention group
Group type: COMPARATOR
Intervention: Placebo run-in period
Number of subjects: 391
Study 7956538 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of low dosed or low molecular heparin into the contralateral abdominal wall
Number of subjects: 108
Study 7956538 — intervention group
Group type: COMPARATOR
Intervention: Injection of low dosed or low molecular heparin into the thigh
Number of subjects: 108
Study 2955717 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg/kg ATR
Number of subjects: 44
Study 2955717 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg DTC
Number of subjects: 44
Study 2955717 — intervention group
Group type: COMPARATOR
Intervention: Saline (NS)
Number of subjects: 44
Study 30161248 — intervention group
Group type: EXPERIMENTAL
Intervention: Few Touch Application (mHealth intervention)
Number of subjects: 101
Study 25861808 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (5000 IU/day)
Number of subjects: 39
Study 25861808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 24371304 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (continuing group)
Number of subjects: 57
Study 24371304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (discontinuing group)
Number of subjects: 57
Study 22326387 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (HD)
Number of subjects: 96
Study 22326387 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (RD)
Number of subjects: 96
Study 19473893 — intervention group
Group type: EXPERIMENTAL
Intervention: i-Scan
Number of subjects: 69
Study 19473893 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy (Methylene blue 0.1%)
Number of subjects: 69
Study 19473893 — intervention group
Group type: COMPARATOR
Intervention: HD+ alone
Number of subjects: 69
Study 19473893 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy
Number of subjects: 69
Study 18578171 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous ozone (Healozone, KaVo 1600 ppm) for 60 seconds
Number of subjects: 31
Study 18578171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 31
Study 18578171 — intervention group
Group type: COMPARATOR
Intervention: Comparison of test and control teeth
Number of subjects: 31
Study 16225359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziconotide (PRIALT®)
Number of subjects: 0
Study 16225359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11955537 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 401